表膜近距放射治疗用于既往接受过治疗的新生血管性年龄相关性黄斑变性:MERLOT随机对照试验第36个月结果
MERLOT随机对照手术器械试验纳入24家英国医院慢性活动性新生血管性年龄相关性黄斑变性(nAMD)患者,随机接受睫状体平坦部玻璃体切除联合24 Gy表膜近距放射治疗(EMB)加按需雷珠单抗(n=224)或按需雷珠单抗单药治疗(n=119)。第36个月结果显示EMB未减少抗VEGF注射次数,且最佳矫正视力(BCVA)较单药治疗更差。
要点
- 第1至36个月注射次数EMB组12.1±8.1次 vs 雷珠单抗组11.4±6.1次,差异无统计学显著。
- 36个月BCVA变化EMB组-19.7±18.5字母 vs 雷珠单抗组-4.8±12.5字母,差异-14.9字母(95%CI -18.5至-11.2,p<0.0001)。
- 第24个月有微血管异常(MVA)的20例EMB治疗者第36个月BCVA变化与无MVA者相似(-21.8 vs -19.4字母,p=0.65)。
核心结论
- EMB不在试验内或试验外减少抗VEGF注射次数,且与抗VEGF单药治疗相比BCVA更差。
研究设计与样本
- 关键性随机对照手术器械试验,从24家英国医院招募接受玻璃体腔雷珠单抗治疗的慢性nAMD患者。
- 参与者随机接受睫状体平坦部玻璃体切除联合24 Gy EMB加按需雷珠单抗(n=224)或按需雷珠单抗单药治疗(n=119)。
- 虽无法设盲,由设盲临床医生评估BCVA和影像;第24个月后参与者回归标准治疗(雷珠单抗或阿柏西普),返回参加第36个月研究访视。
主要发现
- 363例参与者中309例(85.1%)完成第36个月访视。
- 第1至36个月注射次数EMB组12.1±8.1次 vs 雷珠单抗组11.4±6.1次(差异0.7,95%CI -0.9至2.3,p=0.41)。
- 第25至36个月(标准治疗)注射次数EMB组3.6±3.3次(n=200) vs 雷珠单抗组3.9±2.7次(n=102)(差异-0.3,95%CI -1.0至0.4,p=0.43)。
- 36个月BCVA变化EMB组-19.7±18.5字母 vs 雷珠单抗组-4.8±12.5字母(差异-14.9,95%CI -18.5至-11.2,p<0.0001)。
- 第24个月有MVA的20例EMB治疗者第36个月BCVA变化与无MVA的EMB治疗者相似(-21.8 vs -19.4字母,p=0.65)。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIM: To assess the long-term safety and efficacy of epimacular brachytherapy (EMB) for chronic, active, neovascular age-related macular degeneration (nAMD). METHODS: This pivotal, randomised, controlled surgical device trial recruited patients with chronic nAMD receiving intravitreal ranibizumab from 24 UK hospitals. Participants were randomised to either pars plana vitrectomy with 24 Gray EMB and pro re nata (PRN) ranibizumab (n=224) or PRN ranibizumab monotherapy (n=119). Although masking was not possible, masked clinicians assessed best-corrected visual acuity (BCVA) and imaging. After month 24, participants reverted to standard care, with either ranibizumab or aflibercept, returning for a month 36 study visit. RESULTS: Of 363 participants, 309 (85.1%) completed month 36. The number of injections was 12.1±8.1 in the EMB group versus 11.4±6.1 in the ranibizumab group (difference 0.7, 95% CI of difference -0.9 to 2.3, p=0.41) between months 1 and 36, and 3.6±3.3 (n=200) versus 3.9±2.7 (n=102) (difference -0.3, 95% CI of difference -1.0 to 0.4, p=0.43) between months 25 and 36 (standard care). Over 36 months, BCVA change was -19.7±18.5 letters in the EMB group and -4.8±12.5 in the ranibizumab group (difference -14.9, 95% CI of difference -18.5 to -11.2, p<0.0001). The month 36 BCVA of 20 EMB-treated participants with microvascular abnormalities (MVAs) at month 24 was similar to EMB-treated participants without MVAs (-21.8 vs -19.4 letters, p=0.65). CONCLUSION: EMB does not reduce the number of anti-vascular endothelial growth factor (VEGF) injections, either within or outside of a trial setting, and is associated with worse BCVA than anti-VEGF monotherapy. TRIAL REGISTRATION NUMBER: NCT01006538.
引用
- Jackson TL, Soare C, Petrarca C, et al. Epimacular brachytherapy for previously treated neovascular age-related macular degeneration: month 36 results of the MERLOT randomised controlled trial. Br J Ophthalmol. 2022. PMID: 35217515. doi:10.1136/bjophthalmol-2021-320620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。